Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.7554/eLife.61312 http://scihub22266oqcxt.onion/10.7554/eLife.61312 33112236!7723407!33112236     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Elife 2020 ; 9 (ä): ä Nephropedia Template TP {{tp|p=33112236|t=2020. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants |pdf=|usr=}}{{33112236}} gab.com Text Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants JO: Elife http://www.kidney.de/pget.php?&tw=1&pmid=33112236 #FOAvip Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future protection of individuals and populations against SARS-CoV-2. Moreover, passively administered antibodies are among the most promising therapeutic and prophylactic anti-SARS-CoV-2 agents. However, the degree to which SARS-CoV-2 will adapt to evade neutralizing antibodies is unclear. Using a recombinant chimeric VSV/SARS-CoV-2 reporter virus, we show that functional SARS-CoV-2 S protein variants with mutations in the receptor-binding domain (RBD) and N-terminal domain that confer resistance to monoclonal antibodies or convalescent plasma can be readily selected. Notably, SARS-CoV-2 S variants that resist commonly elicited neutralizing antibodies are now present at low frequencies in circulating SARS-CoV-2 populations. Finally, the emergence of antibody-resistant SARS-CoV-2 variants that might limit the therapeutic usefulness of monoclonal antibodies can be mitigated by the use of antibody combinations that target distinct neutralizing epitopes. Twit Text FOAVip Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants ????Elife http://www.kidney.de/pget.php?&tw=1&pmid=33112236 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33112236 #FOAvip English Wikipedia <ref>{{Cite pmid|33112236}}</ref> Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants #MMPMID33112236 Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD Elife 2020[Oct]; 9 (ä): ä PMID33112236show ga Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future protection of individuals and populations against SARS-CoV-2. Moreover, passively administered antibodies are among the most promising therapeutic and prophylactic anti-SARS-CoV-2 agents. However, the degree to which SARS-CoV-2 will adapt to evade neutralizing antibodies is unclear. Using a recombinant chimeric VSV/SARS-CoV-2 reporter virus, we show that functional SARS-CoV-2 S protein variants with mutations in the receptor-binding domain (RBD) and N-terminal domain that confer resistance to monoclonal antibodies or convalescent plasma can be readily selected. Notably, SARS-CoV-2 S variants that resist commonly elicited neutralizing antibodies are now present at low frequencies in circulating SARS-CoV-2 populations. Finally, the emergence of antibody-resistant SARS-CoV-2 variants that might limit the therapeutic usefulness of monoclonal antibodies can be mitigated by the use of antibody combinations that target distinct neutralizing epitopes. |*Mutation[MESH] |Angiotensin-Converting Enzyme 2/metabolism[MESH] |Antibodies, Monoclonal/immunology[MESH] |Antibodies, Neutralizing/*immunology[MESH] |Antibodies, Viral/*immunology[MESH] |Base Sequence[MESH] |COVID-19 Serotherapy[MESH] |COVID-19 Vaccines/*immunology[MESH] |COVID-19/*immunology/*therapy/virology[MESH] |Epitopes/genetics/immunology[MESH] |Genes, Reporter[MESH] |Humans[MESH] |Immunization, Passive[MESH] |Neutralization Tests[MESH] |Protein Domains[MESH] |Protein Isoforms/immunology[MESH] |Reassortant Viruses/immunology[MESH] |Receptors, Virus/metabolism[MESH] |SARS-CoV-2/genetics/*immunology/physiology[MESH] |Selection, Genetic[MESH] |Spike Glycoprotein, Coronavirus/genetics/*immunology/metabolism[MESH] |Vesiculovirus/genetics[MESH]Escape from neutralizing antibodies by SARS-CoV-2 spike protein varian(epmc).pdf DeepDyve Pubget Overpricing